Article Information
History
- August 8, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Pedro Cardoso1,
- Katie G. Young1,
- Anand T.N. Nair2,
- Rhian Hopkins1,
- Andrew P McGovern1,
- Eram Haider2,
- Piyumanga Karunaratne2,
- Louise Donnelly2,
- Bilal A. Mateen3,
- Naveed Sattar4,
- Rury R. Holman5,
- Jack Bowden1,
- Andrew T. Hattersley1,
- Ewan R. Pearson2,
- Angus G. Jones1,
- Beverley M. Shields1,
- Trevelyan J. McKinley1,†,
- John M. Dennis1,†,* and
- The MASTERMIND consortium
- 1University of Exeter Medical School. Address: Institute of Biomedical & Clinical Science, RILD Building, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK
- 2University of Dundee. Address: Division of Molecular & Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK
- 3University College London, Institute of Health Informatics. Address: University College London, 222 Euston Rd, London NW1 2DA, London, UK
- 4Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8TA, UK
- 5Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford. Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford. Address: Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
- ↵*Corresponding author: John M Dennis, Institute of Biomedical & Clinical Science, RILD Building, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK, Email: j.dennis{at}exeter.ac.uk Tel: +44 (0)7734 940921
Posted August 08, 2023.
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
